JASON KATTENHORN: Open Payments
NPI 1386358224 · CARSON CITY, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,940 in 95 payments from 16 companies in 2025. Trend: 2023 $366 · 2024 $1,158 · 2025 $1,940
Food & beverage: $1,940
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $676 |
| PFIZER INC. | 11 | $148 |
| Ipsen Biopharmaceuticals, Inc | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $134 |
| Gilead Sciences, Inc. | 4 | $110 |
| Aimmune Therapeutics, Inc. | 4 | $109 |
| Madrigal Pharmaceuticals | 3 | $99 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $97 |
| QOL Medical, LLC | 4 | $96 |
| Ardelyx, Inc. | 5 | $95 |
Products named: RINVOQ, SKYRIZI, VOWST, IQIRVO, REZDIFFRA, XIFAXAN, Sucraid, IBSRELA.
Industry payments across NV — which companies pay providers there.
